8 March 2018

PDMR Dealing

March 8, 2018, LONDON – Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on March 7, 2018, Dr. Jan-Anders Karlsson, Chief Executive Officer of the Company, purchased 3,250 ordinary shares of 5 pence each in the Company (the “Ordinary Shares”) at a price of 148.64 pence per Ordinary Share.  Following the acquisition, Dr. Karlsson will have an interest in the Company of 92,400 Ordinary Shares, representing 0.09% of the Company’s issued share capital.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

   

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Jan-Anders Karlsson

2

Reason for the notification


a)


Position/status

Chief Executive Officer

b)

Initial notification/Amendment

Initial notification

 

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Verona Pharma plc

b)

LEI

213800EVI6O6J3TIAL06

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument
Identification code

Ordinary Shares of 5 pence each
GB00BYW2KH80

b)

Nature of the transaction

Jan-Anders Karlsson purchased 3,250 Ordinary Shares

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

148.64 pence per Ordinary Share

3,250 Ordinary Shares

d)

Aggregated information
-         Aggregated volume
-         Price

 

N/A

e)

Date of the transaction

7 March 2018

f)

Place of the transaction

London Stock Exchange, AIM

For further information, please contact:

Verona Pharma plc

Tel: +44 (0)20 3283 4200

Jan-Anders Karlsson, Chief Executive Officer

info@veronapharma.com

   

Stifel Nicolaus Europe Limited (Nominated Adviser
and UK Broker)

Tel: +44 (0) 20 7710 7600
SNELVeronaPharma@stifel.com

Stewart Wallace / Jonathan Senior / Ben Maddison

 

 


For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell / James White
Tel: +44 (0)20 7496 3000

 

 

FTI Consulting
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)
James Heins
Tel: +1 203-682-8251
James.Heins@icrinc.com

Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us